Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL

Jyotsana Singh, John R. Sanchez II, Chaomei Liu, Bailey Slawin, Nitin Jain, William G. Wierda, Kai Zhang, Michael Niesman, James S. Blachly, Jennifer A. Woyach, Deepa Sampath

Blood (2023) 142 (Supplement 1): 2283.

https://doi.org/10.1182/blood-2023-189378

Published: 2023

Journal Articles

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Blood (2023) 142 (Supplement 1): 416.

https://doi.org/10.1182/blood-2023-178259

Published: 2023

Journal Articles

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 2260.

https://doi.org/10.1182/blood-2023-182024

Published: 2023

Journal Articles

Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors

Vishakha Anand Pawar, Akanksha Aradhya, Daniel Galvan, Gautam Borthakur, Swami P. Iyer, Mark Kirschbaum, David Blake, Tapan M. Kadia, Deepa Sampath, Francisco Vega

Blood (2023) 142 (Supplement 1): 4192.

https://doi.org/10.1182/blood-2023-178256

Published: 2023

Journal Articles

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Anna Skwarska, Vinitha Mary Kuruvilla, Qi Zhang, Sovira Chaudhry, Naval Daver, Krystal Watkins, Callum Mortimer Sloss, Patrick A. Zweidler-McKay, Deepa Sampath, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2023-187018

Published: 2023

Journal Articles

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Daisy Diaz Rohena, Arnau Peris Cuesta, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Charmelle Williams, Wanyi Hu, Peiyi Zhang, Philip Thompson, William G. Wierda, Nitin Jain, Sachet Shukla, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2023) 142 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2023-188250

Published: 2023

Journal Articles

MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL

Jyotsana Singh, Daisy Diaz Rohena, Chaomei Liu, Bailey Slawin, Janani Ravikrishnan, Nitin Jain, William G. Wierda, Kai Zhang, Michael Niesman, Jennifer A. Woyach, Deepa Sampath

Blood (2022) 140 (Supplement 1): 9857–9858.

https://doi.org/10.1182/blood-2022-168391

Published: 2022

Journal Articles

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Daisy Diaz Rohena, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Wanyi Hu, Peiyi Zhang, Philip A. Thompson, William G. Wierda, Nitin Jain, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2022) 140 (Supplement 1): 497–498.

https://doi.org/10.1182/blood-2022-168345

Published: 2022

Journal Articles

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD + Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 681–682.

https://doi.org/10.1182/blood-2022-165573

Published: 2022

Journal Articles

Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax

Janani Ravikrishnan, Elizabeth M. Muhowski, Tzung-Huei Lai, Shrilekha Misra, Daisy Diaz Rohena, Felai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, Yue Shen, John C. Byrd, Deepa Sampath, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 679.

https://doi.org/10.1182/blood-2021-151852

Published: 2021

Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2021) 138 (Supplement 1): 2626.

https://doi.org/10.1182/blood-2021-154195

Published: 2021

Journal Articles

Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation

Daisy Diaz Rohena, Janani Ravikrishnan, Chaomei Liu, Guangrong Zheng, Daohong Zhou, Peiyi Zhang, William G. Wierda, Nitin Jain, Jennifer A. Woyach, Deepa Sampath

Blood (2021) 138 (Supplement 1): 2252.

https://doi.org/10.1182/blood-2021-151982

Published: 2021

Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Blood (2021) 138 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2021-154279

Published: 2021

Journal Articles

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Hua-Jay J. Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, Jan A. Burger, Philip A. Thompson, Alessandra Ferrajoli, Zeev E. Estrov, Koji Sasaki, Deepa Sampath, Guilin Tang, Xuemei Wang, Hagop Kantarjian, Michael J. Keating, William G. Wierda, Nitin Jain

Blood (2021) 138 (Supplement 1): 394.

https://doi.org/10.1182/blood-2021-146432

Published: 2021

Journal Articles

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BT K/PLCG2 mutations

Fabienne Lucas, Karylin Larkin, C. Thomas Gregory, Shelley Orwick, Tzyy-Jye Doong, Arletta Lozanski, Gerard Lozanski, Shrilekha Misra, Apollinaire Ngankeu, Hatice Gulcin Ozer, Deepa Sampath, Shanmugapriya Thangavadivel, Selen A. Yilmaz, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach, James S. Blachly

Blood (2020) 135 (24): 2192–2195.

https://doi.org/10.1182/blood.2019003722

Published: 2020

Includes: Supplemental data

Journal Articles

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Elizabeth M. Muhowski, Amy M. Lehman, M.A.S, Sean D. Reiff, PhD, Janani Ravikrishnan, Rose Mantel, Shrilekha Misra, Michael Niesman, PhD, Kai Zhang, MD, James S. Blachly, MD, Deepa Sampath, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 2077.

https://doi.org/10.1182/blood-2019-128871

Published: 2019

Journal Articles

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

Janani Ravikrishnan, Tzung-Huei Lai, PhD DVM, Elizabeth Muhowski, Lindsey Brinton, PhD, Katie Williams, MS, Alexandria Thompson, James S. Blachly, MD, Hatice Gulcin Ozer, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer Woyach, MD, Deepa Sampath, PhD

Blood (2019) 134 (Supplement_1): 2526.

https://doi.org/10.1182/blood-2019-128574

Published: 2019

Journal Articles

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Shaneice Renee Mitchell, BS, Nicole Grieselhuber, MD PhD, Yerdanos Asemelash, Matthew Cannon, BA, Shelley Orwick, BS, Pratibha Sharma, PhD, Virginia Goettl, DVM, PhD, Vinay K Puduvalli, MD MBBS, Deepa Sampath, PhD, Alice S. Mims, MD, James S. Blachly, MD, Amy M. Lehman, PhD, Bonnie K. Harrington, DVM, Justin Breitbach, Erkan Baloglu, William Senapedis, PhD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3931.

https://doi.org/10.1182/blood-2018-99-119358

Published: 2018

Journal Articles

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

Janani Ravikrishnan, BS, Tzung-Huei Lai, PhD, Shaneice Renee Mitchell, BS, Pei-Jung Wu, BS, Shelley Orwick, BS, Chaomei Liu, PhD, Jennifer A. Woyach, MD, Alice S. Mims, MD, William Plunkett, PhD, Vinay K Puduvalli, MD MBBS, John C. Byrd, MD, Rosa Lapalombella, PhD, Deepa Sampath, PhD

Blood (2018) 132 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2018-99-116485

Published: 2018

Journal Articles

Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations

Alice S. Mims, MD, Jessica Kohlschmidt, PhD, Ann-Kathrin Eisfeld, MD, Krzysztof Mrózek, MDPhD, James S. Blachly, MD, Shelley Orwick, BS, Dimitrios Papaioannou, MD, Deedra Nicolet, MS, Deepa Sampath, PhD, Richard M. Stone, MD, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, John C. Byrd, MD, Clara D. Bloomfield, MD

Blood (2018) 132 (Supplement 1): 1488.

https://doi.org/10.1182/blood-2018-99-114704

Published: 2018

NARROW

MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD + Acute Myeloid Leukemia

Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BT K/PLCG2 mutations

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only